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Introduction
The E2F transcription factor family regulates fundamental cellular processes by 
controlling the transcription of a plethora of genes involved in proliferation, differentiation and 
apoptosis. E2F activity is complex. Based on function studies, the originally identified E2F 
family members (E2F1-6) can be divided into two subclasses, transcription activators and 
repressors.  Members of the activator subclass, consisting of E2F1, E2F2 and E2F3, bind E2F 
targets and induce gene expression.  The repressor subclass composed of E2F4, E2F5 and E2F6, 
suppresses expression of their targets (Cam and Dynlacht, 2003).  Hetero-dimerization with DP 
proteins (dimerization partners) is required for E2F function (Trimarchi and Lees, 2002). 
Recently, the complexity of this family was further extended by the identification of two novel 
family members, named as E2F7 and E2F8 (de Bruin et al., 2003; Di Stefano et al., 2003; Logan 
et al., 2004; Maiti et al.,
2005; Christensen et al.,
2005; Logan et al., 2005).
E2F7 and E2F8 are 
conserved in mice and 
humans (Li et al., 2008).  
These two novel E2F family members share unique characteristics, and have several salient 
features that distinguish them from other family members. The most notable feature of E2F7 and 
E2F8 is that they each possess two DNA binding domains (E2F1-6 only have one DBD) and lack 







Figure 1.  Schematic representation of the E2F transcription factors. A highly conserved 
DNA binding domain (DBD) is the hallmark of the E2F family of transcription factors.  
Different from other E2Fs, E2F7 and E2F8 have two distinct DBDs. DP dimerization domain 







(Figure 1).  Other features include their abilities to homo-dimerize with themselves and hetero-
dimerize with each other, to silence target gene expression, and to block cellular proliferation 
when overexpressed in vitro (de Bruin et al., 2003; Di Stefano et al., 2003; Maiti et al., 2005).
However, as the most recently identified and the least studied E2Fs, in vivo functions of E2F7 
and E2F8 remain unknown.
The molecular understanding of how proliferation, differentiation and apoptosis is 
regulated in normal and cancer cells remains as a cornerstone to the development of any future 
treatment of cancer patients in humans. While E2Fs have been shown to play a key role in 
controlling these events, our understanding has been hampered by the fact that it was only very 
recently that E2F7 and E2F8, the last two family members contributing to “E2F” activity, were 
identified.  In this regard, the complete understanding of the E2F activity will only be possible 
until physiological functions of E2F7 and E2F8 are fully revealed. 
Results
Genetic Ablation of E2f7 and E2f8 in vivo Leads to Embryonic Lethality and Massive Apoptosis 
in the Fetus.
To investigate E2F7 and E2F8 function in vivo, we utilized knockout strategies to disrupt 
E2f7 and E2f8 genes
in mice.  Intercrosses 
between heterozygous 
E2f7 or E2f8 animals
(E2f7+/- and E2f8+/-, 
respectively) resulted 
expected             5           28          22                 19           75          56                    13          47            34
expected             7           20          13                 16            43          28                     8          23      14
expected              - 5             5                       3          16          13                       3          10            8
expected          - - 5                         - 4          15                       - 4           10 
expected          8           18          10                      18           39          21             10           21     11 
total
E9.5                6        16      29               16        72(2)  53(1)           12        58(1)    33             299
E11.5               - 6     4                 2        15(2)   14(2)            2(1)  8(1)  0(5)b 62 
E12.5               - - 3                   - 4       17(2)             - 3    0(9)b 38                             
E10.5              9        21      13                7(1) 45      28(1)   4(1)    28(1)  6(7)a 172 
P0                   7        22       16      24        45       17               5     18     0b 154
Table 1: Genotypic analysis of embryos during development
E2f8+/+ E2f8-/-E2f8+/-
() number of dead embryos recovered; Exact binomial test:  a significant (p=0.0015), b highly significant (p<0.0007).
E2f8+/+ E2f8-/-E2f8+/- E2f8+/+ E2f8-/-E2f8+/-
E2f7+/+ E2f7+/- E2f7-/-
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in viable single knockout offspring (SKO, E2f7-/- or E2f8-/-) that appeared normal, were fertile 
and lived to old age (data not shown).  We then explored functional redundancy between E2F7 
and E2F8 by examining the biological consequence of ablating both simultaneously.  To this end, 
we intercrossed E2f7+/-E2f8+/- and E2f7+/-E2f8-/- animals and analyzed the resulting offspring.  
Whereas E2f7-/-E2f8+/- and E2f7+/-E2f8-/- pups were born at the expected Mendelian ratios, no 
double knockout pups (DKO, E2f7-/-E2f8-/-) were found in newborn litters (Table 1, P0), 
demonstrating that at least one allele of E2f7 or E2f8 is required for embryo development and 
viability.  
Analysis at earlier stages of embryonic development revealed that 6 out of 13 DKO 
embryos were alive at embryonic day 10.5 (E10.5) and none were alive at E11.5 (Table 1).  All
DKO embryos identified at E9.5 had a beating heart, but these embryos were noticeably smaller 
than wild type littermates (Figure 
2a, top panels).  Macroscopic 
inspection of embryos did not 
reveal other obvious defects at 
this stage of development.  By 
E10.5, however, vascular defects 
were observed in the embryo 
proper, which were characterized 
by large dilated blood vessels 
associated with multifocal 






























Figure 2. Global 
deletion of E2f7 and 





(a) Gross pictures of 
DKO embryos at E9.5 
(top panels) and 
E10.5 (bottom panels).  
The vascular defects 
in E10.5 E2f7-/-E2f8-/-
embryo are indicated 
by arrows.  (b) 
Embryo sections with 
the indicated 
genotypes were 
analyzed by TUNEL 
assays.  Far left 
panels: low 
magnification pictures 
of whole embryos.  
Right panels: high 
magnification pictures 
of the boxed areas 
from the low 
magnification pictures.  
Apoptotic cells were 






















We then examined proliferation and apoptosis in DKO embryos more closely.  When 
assessed by immunohistochemistry (IHC) using antibodies specific for the S-phase marker BrdU, 
we observed no detectable difference in proliferation between DKO and wild type embryos (data 
not shown).  We did find, however, a massive number of cells labelled by TdT-mediated dUTP 
nick end-labelling (TUNEL) in DKO embryos, indicating widespread apoptosis (Figure 2b).  In 
summary, global deletion of E2f7 and E2f8 resulted in embryonic lethality by E11.5 and a 
spectrum of embryonic defects impacting the vasculature and cell survival.
E2f1 is a Direct Target of E2F7 and 
E2F8 
E2F7 and E2F8 are believed to 
act as transcriptional repressors
(Lammens et al., 2009).  As a first step 
towards understanding the mechanism 
of how E2F7 and E2F8 function, we
utilized chromatin immunoprecipitation 
(ChIP) assays to assess the ability of
E2F7 and E2F8 to bind known E2F 
target promoters, such as E2f1.  To this 
end, chromatin from cells 
overexpressing flag-E2F7 or flag-E2F8 was immunoprecipitated with antibodies specific for the 
flag epitope.  Quantitive PCR assays showed that E2F7 and E2F8 were specifically recruited to 
the E2F binding sites on the E2f1 promoter but not to the irrelevant sequences of E2f1 (control) 
or to the tubulin promoter (Figure 3a, 3b).  This recruitment was specific, since IgG antibodies
Figure 3. E2f1 is a direct 
target of E2F7 and E2F8. 
(a) Chromatin from cells 
overexpressing wild type 
flag-E2F7 (wt) or flag-
E2F7DBD mutant (mut) 
was immunoprecipitated (IP) 
with anti-flag or IgG control 
antibodies.  
Immunoprecipitated DNA 
was amplified using primers 
specific for the E2f1
promoter (E2f1), irrelevant 
sequences in the exon 1 of 
E2f1 and in the tubulin
promoter (control and
tubulin, respectively).  
Quantitive PCR was 
performed in triplicate and 
cycle numbers were 
normalized to 1% of the 
input DNA. (b) Similar ChIP 
experiments were 
performed for E2F8.  (c) 
Expression of E2f1 in MEFs 
was measured by quantitive 
RT-PCR. (d) Western blot 
analysis of MEFs using 
antibodies specific for E2F1. 
Tubulin specific antibodies 
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failed to immunoprecipitate E2f1 promoter sequences.  Moreover, anti-flag antibodies failed to 
immunoprecipitate the E2f1 promoter from cell lysates expressing mutant forms of E2F7 or
E2F8 proteins that are incapable of binding DNA.  
To determine whether the recruitment of E2F7 and E2F8 to the E2f1 promoter had any 
functional consequence on its expression, we examined E2F1 mRNA and protein levels in mouse 
embryo fibroblast (MEF) cells deficient for both E2f7 and E2f8.  Analysis of E2F1 expression in 
DKO cells showed a significant increase in its mRNA and protein levels relative to control 
MEFs (Figure 3c, 3d).  Together, these results suggest that E2F7 and E2F8 directly occupy the 
E2f1 promoter and repress its expression.
DKO Cells are Hypersensitive to DNA-
damage Induced Cell Death
Given the observation that
DKO embryos exhibited massive 
apoptosis and the fact that 
overexpression of E2F1 elicits
apoptosis, especially under DNA-
damage conditions (Stevens and La 
Thangue, 2004), we tested the 
sensitivity of DKO cells to 
camptothecin, a DNA-damage inducing drug.  To this end, wild type and DKO MEFs were 
treated with camptothecin and cell viability was determined by trypan blue exclusion.  
Camptothecin induced a significant acceleration of cell death in DKO MEFs when compared to 
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Figure 4. MEFs 




apoptosis.  (a) MEFs 
with the indicated 
genotypes were mock 
treated with DMSO (-
camptothecin) or with 
camptothecin (+ 
camptothecin). The 
percentage of viable 
cells at the indicated 
time points are 
presented. (b) Light 
microscopy images of 
MEFs treated as in (a).  
(c) Lysates derived from 
MEFs treated as in (a) 
were analyzed by 
Western blotting using 
E2F1 specific antibodies.  
Tubulin-specific 
antibodies were used as 




































expected                   - 5                           6
E9.5                    - 2                     5                    46
Genotypic analysis of E2f1;E2f7;E2f8 embryos during development
E2f1+/+




E12.5                  - - 0(4)a 10
expected                   - - 3
Figure 5. Loss of 
E2f1 suppresses 
apoptosis in E2f7-/-
E2f8-/- embryos. (a) 
Quantification of 
TUNEL-positive cells 
in the indicated 




are presented as the 
average  SD 
percentage. (b)
Genotypic analysis 
of embryos derived 
from E2f1+/-E2f7+/-
E2f8-/- intercrosses 





























































































had the characteristic blebbing morphology of apoptotic cells (Figure 4b).  We also evaluated the 
levels of E2F1 in drug-treated DKO MEFs by Western blotting.  As expected, E2F1 protein 
accumulated to higher levels in drug-treated DKO cells than in similarly treated wild type cells 
(Figure 4c).  These results indicate that E2F7 and E2F8 may attenuate DNA-damage induced 
apoptosis by preventing the aberrant accumulation of E2F1.
Induction of Apoptosis in DKOEmbryos is Dependent on E2F1 
The above findings prompted us to hypothesize that the apoptosis in DKO embryos may
be mediated through induction of E2F1 in vivo.  To test this possibility, E2f7+/-E2f8-/- animals 
were bred with E2f1-/-animals in order to generate E2f7+/-E2f8+/-E2f1-/-mice.  Timed pregnancies 
using these latter 
groups of mice were 
harvested at E9.5 and 
TUNEL assays were 





revealed that E2f1 was a physiologically relevant target, since its loss suppressed the massive 
apoptosis observed in DKO fetuses (Figure 5a).  Together, these results identify E2F7 and E2F8 
as a unique repressive arm of the E2F network that is critical for cell survival by controlling the 
E2F1 apoptotic pathway. Interestingly, however, inactivation of E2f1 failed to prevent the death 
of DKO fetuses (Figure 5b), suggesting that apoptosis is not the leading cause of the observed 
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lethality. In fact, TKO embryos harvested at E10.5 also exhibited dilated vessels and extensive 
hemorrhaging as seen in DKO embryos (data not shown).  
Loss of E2f7 and E2f8 Leads to Profound Placental Defects 
We then sought to determine the primary cause underlying the E11.5 lethality of DKO
embryos and reasoned that identification of the tissues and cells in which E2F7 and E2F8 are 
most critical for embryo development/viability may provide more valuable insight into their 
physiological functions.  To this end, we investigated a possible function of E2F7 and E2F8 in 
the placenta, since defective placentation often results in fetal growth retardation, and if 
sufficiently severe, may lead to mid-gestation lethality (Watson and Cross, 2005).  Histological 
examination of hematoxylin and eosin (H&E)-stained E2f7+/+E2f8+/+ placenta sections showed 
that the placental 
architecture was sponge-
looking and well organized 
by E10.5 (Figure 6a, left 
panels).  In contrast, the 
architecture in DKO 
placentas was severely 
compromised (Figure 6a, 
right panels).  In situ
hybridization and immunofluorescence (IF) staining revealed that the double mutant placentas 
had lower expression levels of spongiotrophoblast- and giant cell-specific markers (Figure 6b














Figure 6. Profound placental defects in E2f7-/-E2f8-/- embryos. (a) E10.5 placenta 
sections with the indicated genotypes were stained with H&E.  The bottom panels 
represent higher magnification images of boxed areas demarcated in the top panels.  
De., Decidua; La., Labyrinth.  (b) Top panels: RNA in situ hybridization analysis of 
Proliferin, a giant cell-specific marker on E9.5 placenta sections having the indicated 
genotypes. Middle and bottom panels: IF staining of E10.5 placenta sections with the 
indicated genotypes using antibodies specific for Placental Lactogen 1 (PL-1), a giant 
cell-specific marker.  The boxed areas in middle panels are shown at higher 












fetuses, these analyses show that double mutant placentas had extensive architectural 
abnormalities and severe differentiation defects. 
Extra-embryonic Functions of E2F7 and E2F8 are Necessary and Sufficient for Embryo Survival. 
The profound placental defects in DKO embryos encouraged us to rigorously evaluate the 
role of E2f7 and E2f8 in the placenta (extra-embryonic compartment). To this end, we took 
advantage of the conditional 
alleles of E2f7 and E2f8
(E2f7loxp and E2f8loxp) and 
different cre recombinases to 
specifically disrupt E2f7 and 
E2f8 function either in placental 
or fetal compartment (Figure 
7a). Cyp19-cre transgenic mice 
express cre in all cell lineages 
of the mouse placenta, but not 
in the embryo proper (Wenzel 
and Leone, 2007).  They were 
used to examine the 
consequence of inactivating 
E2f7 and E2f8 in the placenta.  Genotypic analysis revealed that 8 out of 22 embryos with 
placenta-specific deletion (Cyp19-cre; E2f7loxp/loxpE2f8loxp/loxp) died at E10.5 and all were dead by 
E11.5 (Figure 7a, placental knockout, and data not shown).  Importantly, these E10.5 live 





































Figure 7. Extra-embryonic functions of E2F7 and E2F8 are both 
necessary and sufficient for embryo survival. (a) Embryo cartoon 
pictures of conventional and conditional knockout strategies. Total 
knockout (DKO), placental knockout (Cyp19-cre), and fetal knockout
(Sox2-cre).  The fetal viability was summarized as below.  (b) Phenotypes
of embryos with the indicated genotypes.  Top panels: H&E staining of 
E10.5 placentas.  Bottom panels: Gross appearance of E10.5 fetuses.  
Dilated blood vessels and hemorrhages are indicated by arrows.  Note 





















growth retardation, blood vessel dilation and hemorrhaging (Figure 7b, placental knockout ).  
Thus, we conclude that extra -embryonic functions of E2F7 and E2F8 are critical for embryonic 
development and that their disruption causes the gross abnormalities and E11.5 lethality 
observed in DKO (total knockout) embryos.
We also utilized Sox2-cre transgenic mice to examine the consequence of inactivating 
E2f7 and E2f8 solely in fetal lineages.  Sox2-cre mice express cre in the embryo proper, but not 
in extra-embryonic lineages (Hayashi et al., 2002).  Strikingly, double mutant fetuses supplied 
with a wild type placenta (Sox2-cre;E2f7loxp/-E2f8loxp/-) were carried to term (Figure 7a, fetal 
knockout, and data not shown). These fetuses appeared normal at E10.5 and lacked any of the 
developmental phenotypes characteristic of similarly staged total knockout embryos (Figure 7b, 
fetal knockout, bottom panel).  As expected, E10.5 placentas associated with these fetuses were 
morphologically normal (Figure 7b, fetal knockout, top panel).  Together, these genetic analyses 
demonstrate that extra-embryonic functions of E2F7 and E2F8 are both necessary and sufficient 
for embryo survival.
E2F7 and E2F8 Control Cell C ycle Progression in the Placenta. 
Knowing that the placenta is the critical 
tissue for E2F7 and E2F8 function allows us to 
further dissect cellular processes and molecular 
pathways regulated by these two novel E2Fs.  To 
this end, we performed genome-wide gene 
expression analysis on E10.5 placentas from 
wild type, total knockout and placental knockout 




















Figure 8. Genome-wide gene expression analysis of E10.5 
placenta tissues.  (a) Potential targets of E2F7 and E2F8 are 
presented by a two-set Venn diagram.  Genes differentially 
upregulated (>2-fold, p<0.05) in placenta tissues from total 
knockout and placental knockout embryos are shown as colored 
circles. (b) Pie chart describing major gene function categories of 
49 differentially expressed genes.
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and placental knockout when compared to wild type (Figure 8a).  Quantitive RT-PCR assays 
confirmed these results in a subset of selected targets (data not shown).  Interestingly, functional 
annotation of the 49 gene-set revealed a high percentage of genes involved in the control of G1-S 
and G2-M specific events during cell cycle (Figure 8b).
The above molecular profiles prompted us to examine DKO placentas more closely for 
defects in cell cycle regulation.  We first measured BrdU incorporation in the three main extra-
embryonic lineages: giant cells (TG), spongiotrophoblast (SP) and labyrinth trophoblast (LT).  
This analysis revealed ectopic S phase entry in DKO TG and SP (Figure 9a, 9b).  Surprisingly, 
we also detected many double mutant giant cells in mitosis, as measured by IHC with the mitotic 
marker P-H3 antibodies (Figure 9c, 9d). This was striking because giant cells normally
reduplicate their genome but never undergo mitosis (Varmuza et al., 1988).  
Together, systematic analyses of global gene expression profiles in placental tissues 
identified a transcriptional 
network repressed by 
E2F7 and E2F8 that 
control and coordinate G1-
S and G2-M transitions.  
Disruption of this network 
results in ectopic DNA 
replication, aberrant 











































































































Figure 9. E2F7 and E2F8 regulate cell cycle progression in the placenta. (a) E10.5 
placentas with the indicated genotypes were analyzed by BrdU/PL-1 double 
immunofluorescence staining with BrdU in green, PL-1 in red and DAPI in blue.  Arrows 
indicate the BrdU/PL-1 double positive giant cells.  (b) Percentages of BrdU positive
cells were quantified for the indicated extra-embryonic lineages.  (c) P-H3 immuno-
biochemistry staining.  Arrow points to an aberrant P-H3 positive giant cells. Star marks 
a P-H3 negative giant cell.  (d) Percentages of P-H3 positive cells were quantified for 
the indicated extra-embryonic lineages. All data are presented as the average  SD 
percentage of positive cells.  n, number of placenta samples analyzed for each genetic 
group.  Pairwise comparisons were evaluated by two-tailed Student’s t-tests 













































































































Because of the intense interest in E2Fs as major regulators of the cell cycle and apoptosis, 
individual E2F family members, including E2f1 through E2f6, have been extensively studied in 
vivo by knockout approaches in mice.  Surprisingly, defects in embryos deficient for each of the 
known E2Fs are rather subtle (Attwooll et al., 2004). The virtual absence of cell proliferation 
and apoptotic defects in these embryos raised questions about the physiological importance of 
E2Fs, leaving the impression that these factors must either not be critical for the control of these 
processes in vivo or that there is sufficient functional redundancy among family members to 
accommodate for a deficiency in any single E2F. Here, we show that the disruption of E2f7 or 
E2f8 also had little consequence on mouse development.  Their combined ablation, however,
resulted in widespread apoptosis, profound placental and vascular defects, leading to embryonic 
death by E11.5.
In vitro and in vivo experiments described here provide clear-cut evidence in support of a 
role for E2F7 and E2F8 in the control of apoptosis.  The mechanism of their action involves, at 
least in part, the regulation of E2f1 expression.  ChIP experiments showed that E2F7 and E2F8 
are recruited to the E2f1 promoter.  Consistent with a role in repression of E2f1, genetic 
inactivation of E2f7 and E2f8 resulted in the accumulation of E2f1 mRNA and a corresponding 
increase in its protein product.  More importantly, the accumulation of E2F1 in DKO cells is of 
physiological significance since ablation of E2f1 suppressed the widespread apoptosis observed 
in DKO embryos. Together, these results demonstrate a direct role for E2F7 and E2F8 in the 
control of fetal cell death and highlight the significance of the crosstalk between the E2F family 
members: E2F1, E2F7 and E2F8 (Figure 10).
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In addition to their function in governing E2F1-dependnet apoptosis in the fetus, E2F7 
and E2F8 also play an essential role in extra-embryonic lineages of the placenta. Their 
importance in these lineages was highlighted by 
conditional knockout experiments showing that their 
function in the placenta was both necessary and sufficient 
for embryo viability and development.  Loss of E2f7 and
E2f8 adversely affects cell cycle progression and impairs 
important cell lineage differentiation in the placenta
(Figure 10).  Thus, E11.5 lethality of DKO embryos could 
reflect the high sensitivity of placenta to subtle alterations in cell cycle control and restrictive
requirement of fully developed placenta to maintain a successful pregnancy. Consistent with is 
idea, a recent survey of knockout mice with placental phenotypes revealed a prominent 
association of genes with functions in cell cycle regulation (Rossant and Cross, 2001; Watson 
and Cross, 2005).  While the leading reasons for embryonic lethality in these cases are not well-
defined, our data suggest that these embryos very likely die from placental dysfunction.  
The underlying mechanism of E2F7 and E2F8 action in controlling the timely cell cycle 
progression in the placenta involves the repression of a transcriptional network necessary for 
coordinating G1-S and G2-M transitions. Derepression of G1-S related genes may be viewed to 
drive the ectopic DNA replication observed in DKO SP and TG cells, and derepression of G2-M 
specific genes to contribute to the inappropriate nuclear division observed in double mutant TG 
cells.  Importantly, a significant induction of proliferation was also observed in adult tissues
lacking of E2f7 and E2f8 (data not shown).  Therefore, E2F7 and E2F8 appear to widely function 
E2F7/E2F8
Genes involved 








Figure 10. Current model of E2F7 and E2F8 
function during embryo development. 
Embryo viability
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as important repressors to suppress cellular proliferation.  In this regard, it would be of great 
interest in the future to evaluate their potential suppress or function in cancer study.
In summary, using a combination of mouse genetics, bioinformatics, molecular biology 
and cell biology, this study clearly provides the first in vivo evidence for the physiological
functions of E2F7 and E2F8, and successfully defined the critical cell lineages, cellular processes, 
molecular pathways affected by E2f7 and E2f8 loss. We conclude that E2F7 and E2F8-mediated 
repression controls apoptosis in the fetus and regulates cell cycle progression in the placenta
(Figure 10). These findings not only add significant insights into how the ‘total E2F’ activity 
regulates cellular proliferation, apoptosis and differentiation in normal cells during development,
not also strongly suggest a potential function of E2F7 and E2F8 as tumor suppressors in cancers. 
Methods and Materials
Mouse strains and genotyping -- The conventional and conditional E2f7 and E2f8
knockout mice, Sox2-cre and Cyp19-cre transgenic mice were maintained on a mixed 
background.  Allele-specific primers used for E2f7 and E2f8 PCR genotyping were described 
previously (Li et al., 2008).
BrdU and TUNEL assays -- Pregnant females were injected with BrdU 30 min prior to 
harvesting.  Embryos were fixed in formalin and paraffin embedded-sections were used for 
immunohistochemistry.  Anti-BrdU antibody (MO-0744, DAKO) and Vectastain Elite ABC 
reagent (Vector labs) were used to detect BrdU incorporation according to the manufacturer’s 
instructions.  Apoptotic cells were detected using TUNEL (S7101, Chemican) assays, performed 
according to the manufacturer’s protocol.  All slides were counterstained with hematoxylin.
Chromatin immunoprecipitation (ChIP) assay -- The EZ CHIPTM assay kit (Upstate 
Biotech) was used as described by the manufacturer.  Briefly, human embryonic kidney 293 cells 
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overexpressing flag-E2F7 or flag-E2F8 were crosslinked and chromatin was sonicated.  After 
pre-clearing, antibodies specific to flag or normal IgG (Oncogene) were added to each sample 
and incubated overnight.  Antibody-protein-DNA complexes were recovered by addition of 
Salmon Sperm DNA/Protein G agarose slurry.  Following extensive washing, the complexes 
were eluted and crosslinks were reversed.  Finally, samples were treated with Proteinase K 
(Roche) and Rnase A (Roche) and purified through Qiaquick columns (Qiagen).  Quantitive PCR 
of immunoprecipitated DNA was performed in triplicate and normalized using the threshold 
cycle number for the total input sample.  
Quantitative RT-PCR -- Total RNA was isolated using Qiagen RNA mini-prep columns 
as described by the manufacturer, which included the optional DNase treatment before elution 
from the column.  Reverse transcription (RT) of total RNA was performed using Superscript III 
reverse transcriptase (Invitrogen) and RNAse Inhibitor (Roche). Quantitative PCR was 
performed using a BioRad iCycler and reactions were performed in triplicate and relative 
amounts of cDNA were normalized to GAPDH.  
Western blotting and antibodies --Western blotting analyses were performed by standard 
procedures.  Primary antibody was detected using horseradish-peroxidase-conjugated secondary 
antibodies and ECL reagents as described by the manufacturer (Amersham Biosciences).  The 
following commercial antibodies were used: E2F1 (C-20, Santa Cruz), tubulin (T6199, Sigma).  
Cell culture, proliferation and viability assay -- Mouse embryonic fibroblasts (MEFs) 
were isolated from E13.5 embryos.  Immortalized cell lines (E2f7loxp/loxpE2f8loxp/loxp) were 
generated from primary MEFs using the standard 3T9 protocol and treated with retrovirus 
expressing cre recombinase using standard methods. To measure the sensitivity to apoptosis in 
vitro, MEFs were plated at approximate 30% confluency and treated with 20µm camptothecin 
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(Sigma) 24h after plating.  Media was changed after 18h treatment, and samples were harvested 
at specific intervals as indicated.  Cell viability was determined by trypan blue exclusion. 
RNA in situ hybridization -- In situ hybridization was performed on E9.5 placenta 
sections using the standard protocol that was modified for paraffin-embedded sections.  These 
modifications were deparaffinization in xylene and Proteinase K digestion.  Radio-labelled
probes were generated by in vitro transcription of Proliferin plasmid with either T7 RNA 
polymerase (Roche) using both 35S-CTP and 35S-UTP.  
Genome-wide gene expression analysis --Total RNA was isolated using Qiagen RNA 
mini-prep columns according to the manufacturer’s protocol.  Global gene expression analysis 
was performed on Affymetrix Mouse Genome 430 2.0 arrays.  Expression values were adjusted 
by quantile normalization and log2 transformation with RMAExpress, and data were analyzed 
with BRB-ArrayTools 3.7.0.
Histological analysis and immunostaining -- Placenta samples were fixed in formalin and 
embedded in paraffin.  Standard hematoxylin and eosin (H&E) staining was used for general 
histopathological analysis.  For Immunohistochemistry, slides were probed with primary 
antibodies specifically for Phospho-Histone 3 (P-H3, Ser10) (06-570, Millipore).  Vectastain 
Elite ABC reagent (Vector labs) and DAB peroxidase substrate kit (Vector labs) were used in 
combination to detect P-H3 signals by following the manufacturer’s instructions.  Samples were 
counterstained with hematoxylin.  Giant cells during S-phase transition were detected by double 
immunofluorescence staining using BrdU and PL-1 antibodies.  Nuclear DNA was 
counterstained with DAPI.  
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